524684-52-4

Usage

Uses

Used in Pharmaceutical Industry:
Prinaberel is used as a pharmaceutical agent for its potent ERβ agonist properties, displaying over 200-fold selectivity for ERβ over ERα. This makes it a valuable compound for the development of drugs targeting specific hormone receptor pathways.
Used in Hormone Receptor Research:
Prinaberel is used as a research tool in the field of hormone receptor research, particularly for studying the functions and interactions of ERβ and ERα. Its high selectivity allows for more targeted and specific investigations into the roles of these receptors in various biological processes.
Used in Drug Development:
Prinaberel is used in the development of new drugs that aim to target the ERβ receptor with high specificity. This can lead to the creation of more effective and safer medications for treating conditions related to hormone receptor imbalances or dysfunctions.
Used in Hormone Therapy:
Prinaberel, due to its potent ERβ agonist properties, can be used in hormone therapy to modulate the activity of the estrogen receptor beta. This may have potential applications in treating conditions that are influenced by the hormonal balance, such as certain types of cancer or menopausal symptoms.

InChI:InChI=1/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2

Upstream product

• 115929-59-4 6-bromo-4-methoxy-2-nitrophenol 
• 74-85-1 ethene 
• 544704-73-6 7-bromo-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol 
• 629-14-1 monoethylene glycol diethyl ether 
• 7486-35-3 tri-n-butyl(vinyl)tin 
• 123-91-1 1,4-dioxane 
• 544704-84-9 4-[5-(acetyloxy)-1,3-benzoxazol-2-yl]-7-vinyl-2-fluorophenyl acetate 
• 544704-81-6 5-{[tert-butyl(dimethyl)silyl]oxy}-2-(4-{[tert-butyl(dimethyl)silyl]oxy}-3-fluorophenyl)-7-vinyl-1,3-benzoxazole 
• 206872-01-7 2-amino-6-bromo-4-methoxyphenol 
• 3907-15-1 3-fluoro-4-methoxybenzoylchloride 
• 403-20-3 3-fluoro-p-anisic acid 
• 1568-70-3 4-methoxy-2-nitrophenol 
• 544704-74-7 2-bromo-6-[(3-fluoro-4-methoxybenzoyl)amino]-4-methoxyphenyl-3-fluoro-4-methoxybenzoate 
• 544704-75-8 7-bromo-2-(3-fluoro-4-methoxyphenyl)-5-methoxy-1,3-benzoxazole 

Downstream Products

• 877172-77-5 2-(3'-fluoro-4'-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-sulfate 
• 877172-75-3 2-(3'-fluoro-4'-sulfate-phenyl)-7-vinyl-1,3-benzoxazol-5-ol 
• 1030596-32-7 2-(3-fluoro-4-tert-butyldimethylsilyloxyphenyl)-7-vinylbenzooxazol-5-ol 
• 544704-81-6 5-{[tert-butyl(dimethyl)silyl]oxy}-2-(4-{[tert-butyl(dimethyl)silyl]oxy}-3-fluorophenyl)-7-vinyl-1,3-benzoxazole 
• 1178586-96-3 2-[3-fluoro-4-(phosphonooxy)phenyl]-7~vinyl-1,3-benzoxazol-5-yl dihydrogen phosphate 
• 1178586-92-9 2-fluoro-4-(5-hydroxy-7-vinylbenzo[d]oxazol-2-yl)phenyl dihydrogen phosphate 
• 909281-15-8 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol monohydrate 
• 544705-42-2 7-(2-bromo-1-fluoroethyl)-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol 
• 1178586-90-7 diethyl 2-fluoro-4-(5-hydroxy-7-vinylbenzo[d]oxazol-2-yl)phenyl phosphate 
• 1178586-95-2 2-{4-[(diethoxyphosphoryl)oxy]-3-fluorophenyl}-7-vinyl-1,3-benzoxazol-5-yl diethyl phosphate 
• 544704-84-9 4-[5-(acetyloxy)-1,3-benzoxazol-2-yl]-7-vinyl-2-fluorophenyl acetate 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION

The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.

CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL

The present invention is directed to an anhydrate crystal form (Form D) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.

PHARMACEUTICAL FORMULATIONS OF AN ANHYDROUS CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL

The present invention is directed to pharmaceutical formulations of an anhydrous crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.

Process for the purification of substituted benzoxazole compounds

The present invention provides processes for the purification of substituted benzoxazole compounds, and in particular 2-(3-fluoro-4-hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol. The processes include recrystallizing the compound from a solution comprising ace

Process for the preparation of substituted benzoxazole compounds

The present invention relates to processes for the preparation of substituted benzoxazole compounds, and in particular 2-(3-fluoro-4-hydroxy-phenyl)-7-vinyl-benzoxazol-5-ol. The processes include the vinylation of a substituted benzoxazole compound having

Prodrug substituted benzoxazoles as estrogenic agents

This invention provides estrogen receptor modulators of formula I, having the structure wherein Q, Q2, R1, R2, R2a, R3, R3a, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands

New diphenolic azoles as highly selective estrogen receptor-β agonists are reported. The more potent and selective analogues of these series have comparable binding affinities for ERβ as the natural ligand 17β-estradiol but are > 100-fold selective over ERα. Our design strategy not only followed a traditional SAR approach but also was supported by X-ray structures of ERβ cocrystallized with various ligands as well as molecular modeling studies. These strategies enabled us to take advantage of a single conservative residue substitution in the ligand-binding pocket, ERα Met421 → ERβ Ile373, to optimize ERβ selectivity. The 7-position-substituted benzoxazoles (Table 5) were the most selective ligands of both azole series, with ERB-041 (117) being >200-fold selective for ERβ. The majority of ERβ selective agonists tested that were at least sim;50-fold selective displayed a consistent in vivo profile: they were inactive in several models of classic estrogen action (uterotrophic, osteopenia, and vasomotor instability models) and yet were active in the HLA-B27 transgenic rat model of inflammatory bowel disease. These data suggest that ERβ-selective agonists are devoid of classic estrogenic effects and may offer a novel therapy to treat certain inflammatory conditions.

Substituted benzoxazoles as estrogenic agents

This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.